During the last decade, special attention has been converged on immune checkpoint inhibitors (ICIs), as exemplified by anti-PD-1/PD-L1 (programmed cell death-1/programmed cell death ligand 1), that have revolutionized the way to manage advanced HCC. Here, PDCD1 is linked to hepatocellular carcinoma.